These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 15557524)
21. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Troppmann C; Pierce JL; Gandhi MM; Gallay BJ; McVicar JP; Perez RV Transplantation; 2003 Jul; 76(2):426-9. PubMed ID: 12883205 [TBL] [Abstract][Full Text] [Related]
22. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Renders L; Steinbach R; Valerius T; Schöcklmann HO; Kunzendorf U Kidney Blood Press Res; 2004; 27(3):181-5. PubMed ID: 15256815 [TBL] [Abstract][Full Text] [Related]
23. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989 [TBL] [Abstract][Full Text] [Related]
25. [The first experience with sirolimus (Rapamune) after kidney transplantation in Lithuania]. Asakiene E; Rainiene T; Dainys B Medicina (Kaunas); 2005; 41 Suppl 1():93-100. PubMed ID: 15901984 [TBL] [Abstract][Full Text] [Related]
26. Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients. Kasner SE; Sheth KN; Wu GF; Messe SR; Wolf RL Neurology; 2005 Jul; 65(2):337-8; author reply 337-8. PubMed ID: 16043820 [No Abstract] [Full Text] [Related]
27. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study. Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006 [TBL] [Abstract][Full Text] [Related]
28. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Neff GW; Montalbano M; Tzakis AG Transplant Proc; 2003 May; 35(3 Suppl):209S-216S. PubMed ID: 12742498 [TBL] [Abstract][Full Text] [Related]
29. Sirolimus Associated with Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial. Kojima CA; Nga HS; Takase HM; Bravin AM; Martinez Garcia MFF; Garcia PD; Contti MM; de Andrade LGM Exp Clin Transplant; 2018 Jun; 16(3):301-306. PubMed ID: 28836934 [TBL] [Abstract][Full Text] [Related]
30. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. Lobach NE; Pollock-Barziv SM; West LJ; Dipchand AI J Heart Lung Transplant; 2005 Feb; 24(2):184-9. PubMed ID: 15701435 [TBL] [Abstract][Full Text] [Related]
32. Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy. Chen J; Li L; Wen J; Tang Z; Ji S; Sha G; Cheng Z; Sun Q; Cheng D; Liu Z Transplant Proc; 2008 Jun; 40(5):1411-5. PubMed ID: 18589119 [TBL] [Abstract][Full Text] [Related]
33. [De novo hemolytic uremic syndrome in a kidney-pancreas recipient in the postoperative period]. Gutiérrez de la Fuente C; Sola E; Alférez MJ; Navarro A; Cabello M; Burgos D; González Molina M Nefrologia; 2004; 24 Suppl 3():3-6. PubMed ID: 15219059 [TBL] [Abstract][Full Text] [Related]
35. Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation. Hayes D; Adler B; Turner TL; Mansour HM Pediatr Neurol; 2014 Mar; 50(3):272-5. PubMed ID: 24405697 [TBL] [Abstract][Full Text] [Related]
36. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. Hakeam HA; Al-Jedai AH; Raza SM; Hamawi K Ann Transplant; 2008; 13(2):46-53. PubMed ID: 18566560 [TBL] [Abstract][Full Text] [Related]
37. Effect of Converting From Calcineurin Inhibitor- to Sirolimus-Based Immunosuppressant Regimen on Breast Fibroadenoma Among Kidney Transplant Patients. Kim MJ; Kim BW; Yoon YC; Seo WI; Park YM; Kang SW; Kim TH; Kim YH Transplant Proc; 2019; 51(6):1848-1852. PubMed ID: 31256869 [TBL] [Abstract][Full Text] [Related]
38. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977 [TBL] [Abstract][Full Text] [Related]
39. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. van Gelder T; ter Meulen CG; Hené R; Weimar W; Hoitsma A Transplantation; 2003 Mar; 75(6):788-91. PubMed ID: 12660502 [TBL] [Abstract][Full Text] [Related]
40. Causes of sirolimus discontinuation in 97 liver transplant recipients. Panaro F; Piardi T; Gheza F; Ellero B; Audet M; Cag M; Cinqualbre J; Wolf P Transplant Proc; 2011 May; 43(4):1128-31. PubMed ID: 21620069 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]